Premier Biomedical, Inc. (OTCBB: “BIEI”) a biopharmaceutical company
focused on developing and commercializing innovative immune system
manipulation therapies for breast cancer, Alzheimer’s disease, multiple
sclerosis (MS), traumatic brain injury (TBI), and others today announced
that the United States Patent Office approved a patent on their
proprietary medication “Feldetrex ™”, which is designed to relieve the
symptoms of neuropathic pain and fibromyalgia.
for Premier Biomedical, Inc. (BIEI) Announces Important Patent Award for a Potential Multi-Billion Dollar Drug for the Treatment of Fibromyalgia and Neuralgia investment picks